Lilly, With Tirzepatide Supply Issues Addressed, Raises Guidance By $3bn
Obesity, Diabetes Blockbusters Lead 36% Revenue Growth
Lilly now expects to bring in between $45.4bn and $46.6bn in total revenue this year, thanks mainly to continued growth for Mounjaro and Zepbound.
